98 related articles for article (PubMed ID: 26577506)
1. Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.
Chlebowski RT; Wakelee H; Pettinger M; Rohan T; Liu J; Simon M; Tindle H; Messina C; Johnson K; Schwartz A; Gass M; Wactawski-Wende J
Clin Lung Cancer; 2016 Jan; 17(1):10-7.e1. PubMed ID: 26577506
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
Chlebowski RT; Schwartz AG; Wakelee H; Anderson GL; Stefanick ML; Manson JE; Rodabough RJ; Chien JW; Wactawski-Wende J; Gass M; Kotchen JM; Johnson KC; O'Sullivan MJ; Ockene JK; Chen C; Hubbell FA;
Lancet; 2009 Oct; 374(9697):1243-51. PubMed ID: 19767090
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
Chlebowski RT; Anderson GL; Manson JE; Schwartz AG; Wakelee H; Gass M; Rodabough RJ; Johnson KC; Wactawski-Wende J; Kotchen JM; Ockene JK; O'Sullivan MJ; Hubbell FA; Chien JW; Chen C; Stefanick ML
J Natl Cancer Inst; 2010 Sep; 102(18):1413-21. PubMed ID: 20709992
[TBL] [Abstract][Full Text] [Related]
4. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
Chlebowski RT; Anderson GL; Gass M; Lane DS; Aragaki AK; Kuller LH; Manson JE; Stefanick ML; Ockene J; Sarto GE; Johnson KC; Wactawski-Wende J; Ravdin PM; Schenken R; Hendrix SL; Rajkovic A; Rohan TE; Yasmeen S; Prentice RL;
JAMA; 2010 Oct; 304(15):1684-92. PubMed ID: 20959578
[TBL] [Abstract][Full Text] [Related]
5. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer after use of estrogen plus progestin in postmenopausal women.
Chlebowski RT; Kuller LH; Prentice RL; Stefanick ML; Manson JE; Gass M; Aragaki AK; Ockene JK; Lane DS; Sarto GE; Rajkovic A; Schenken R; Hendrix SL; Ravdin PM; Rohan TE; Yasmeen S; Anderson G;
N Engl J Med; 2009 Feb; 360(6):573-87. PubMed ID: 19196674
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.
Chlebowski RT; Anderson GL; Aragaki AK; Prentice R
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26546117
[TBL] [Abstract][Full Text] [Related]
8. Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
Tao MH; Dai Q; Chen S; Freudenheim JL; Rohan T; Wakelee H; Datta M; Wactawski-Wende J
Lung Cancer; 2017 Aug; 110():42-47. PubMed ID: 28676217
[TBL] [Abstract][Full Text] [Related]
9. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.
Ritenbaugh C; Stanford JL; Wu L; Shikany JM; Schoen RE; Stefanick ML; Taylor V; Garland C; Frank G; Lane D; Mason E; McNeeley SG; Ascensao J; Chlebowski RT;
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2609-18. PubMed ID: 18829444
[TBL] [Abstract][Full Text] [Related]
10. Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies.
Schwartz AG; Ray RM; Cote ML; Abrams J; Sokol RJ; Hendrix SL; Chen C; Chlebowski RT; Hubbell FA; Kooperberg C; Manson JE; O'Sullivan MJ; Rohan T; Stefanick ML; Wactawski-Wende J; Wakelee H; Simon MS
J Thorac Oncol; 2015 Jul; 10(7):1004-13. PubMed ID: 25852020
[TBL] [Abstract][Full Text] [Related]
11. Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort.
Brinton LA; Schwartz L; Spitz MR; Park Y; Hollenbeck AR; Gierach GL
Cancer Causes Control; 2012 Mar; 23(3):487-96. PubMed ID: 22367699
[TBL] [Abstract][Full Text] [Related]
12. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.
Roth JA; Etzioni R; Waters TM; Pettinger M; Rossouw JE; Anderson GL; Chlebowski RT; Manson JE; Hlatky M; Johnson KC; Ramsey SD
Ann Intern Med; 2014 May; 160(9):594-602. PubMed ID: 24798522
[TBL] [Abstract][Full Text] [Related]
13. Menopausal hormone therapy and breast cancer mortality: clinical implications.
Chlebowski RT; Anderson GL
Ther Adv Drug Saf; 2015 Apr; 6(2):45-56. PubMed ID: 25922653
[TBL] [Abstract][Full Text] [Related]
14. Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative.
Wang A; Qin F; Hedlin H; Desai M; Chlebowski R; Gomez S; Eaton CB; Johnson KC; Qi L; Wactawski-Wende J; Womack C; Wakelee HA; Stefanick ML
Int J Cancer; 2016 Nov; 139(10):2178-92. PubMed ID: 27439221
[TBL] [Abstract][Full Text] [Related]
15. Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.
Gass M; Larson J; Cochrane B; Manson JE; Lane D; Barnabei V; Ockene J; Stefanick ML; Mouton C
Menopause; 2018 Mar; 25(3):252-264. PubMed ID: 29112594
[TBL] [Abstract][Full Text] [Related]
16. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative.
Hlatky MA; Ray RM; Burwen DR; Margolis KL; Johnson KC; Kucharska-Newton A; Manson JE; Robinson JG; Safford MM; Allison M; Assimes TL; Bavry AA; Berger J; Cooper-DeHoff RM; Heckbert SR; Li W; Liu S; Martin LW; Perez MV; Tindle HA; Winkelmayer WC; Stefanick ML
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):157-62. PubMed ID: 24399330
[TBL] [Abstract][Full Text] [Related]
17. Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization.
Toh S; Hernández-Díaz S; Logan R; Robins JM; Hernán MA
Epidemiology; 2010 Jul; 21(4):528-39. PubMed ID: 20526200
[TBL] [Abstract][Full Text] [Related]
18. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials.
Bea JW; Zhao Q; Cauley JA; LaCroix AZ; Bassford T; Lewis CE; Jackson RD; Tylavsky FA; Chen Z
Menopause; 2011 Jan; 18(1):44-52. PubMed ID: 20689466
[TBL] [Abstract][Full Text] [Related]
19. Cancer incidence and mortality during the intervention and postintervention periods of the Women's Health Initiative dietary modification trial.
Thomson CA; Van Horn L; Caan BJ; Aragaki AK; Chlebowski RT; Manson JE; Rohan TE; Tinker LF; Kuller LH; Hou L; Lane DS; Johnson KC; Vitolins MZ; Prentice RL
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2924-35. PubMed ID: 25258014
[TBL] [Abstract][Full Text] [Related]
20. Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women's Health Initiative combined hormone therapy trial.
Yang S; Prentice RL
Stat Med; 2015 May; 34(11):1801-17. PubMed ID: 25689356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
